The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Evolution of acquired resistance to anti-cancer therapy
Open accessAbstract
Acquired drug resistance is a major limitation for the successful treatment of cancer. Resistance can emerge due to a variety of reasons including host environmental factors as well as genetic or epigenetic alterations in the cancer cells. Evolutionary theory has contributed to the understanding of the dynamics of resistance mutations in a cancer cell population, the risk of resistance pre-existing before the initiation of therapy, the composition of drug cocktails necessary to prevent the emergence of resistance, and optimum drug administration schedules for patient populations at risk of evolving acquired resistance. Here we review recent advances towards elucidating the evolutionary dynamics of acquired drug resistance and outline how evolutionary thinking can contribute to outstanding questions in the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Stochastic Gene Expression in a Single Cell
Elowitz, M. B., Levine, A. J., Siggia, E. D., & Swain, P. S. (2002) · Science · doi:10.1126/science.1070919 · Cited by 5,441
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Mutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“The T790M point mutation in the epidermal growth factor receptor (EGFR) and focal amplification of the MET proto-oncogene both confer resistance to the EGFR tyrosine kinase inhibitors Tarceva and Iressa (Pao et al., 2005; Engelman et al., 2007), which are used in the treatment of non-small cell lung cancer.”
BackgroundClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 4×
“MDR may stem from changes that limit the accumulation of drugs within cells by decreasing uptake, enhancing efflux, or affecting membrane lipids (Liu et al., 2001), block apoptosis (Lowe et al., 1993), induce mechanisms that detoxify drugs and repair DNA damage (Synold et al., 2001), and modulate the cell cycle (Shah…”
BackgroundInfluentialCancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452 · cited 2×
“oxygen and glucose concentration (Hsu and Sabatini, 2008).”
BackgroundStochasticity in gene expression: from theories to phenotypes
Kærn, M., Elston, T. C., Blake, W. J., & Collins, J. J. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1615 · Cited by 2,320
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“For example, heterogeneity in drug concentration can create niches within tumors that enable novel modes of adaptation, and cellular response to therapies may be inhibited or enhanced based on the local nutrient density (Anderson et al., 2006; Tredan et al., 2007; Wu et al., 2013).”
BackgroundFarber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
The distribution of the numbers of mutants in bacterial populations
Lea, D. E., & Coulson, C. A. (1949) · Journal of Genetics · doi:10.1007/bf02986080 · Cited by 1,450
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
Synold, T. W., Dussault, I., & Forman, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840
Dynamics of chronic myeloid leukaemia
Michor, F., Hughes, T. P., Iwasa, Y., Branford, S., Shah, N. P., Sawyers, C. L., & Nowak, M. A. (2005) · Nature · doi:10.1038/nature03669 · Cited by 833
Self-citationTumor Morphology and Phenotypic Evolution Driven by Selective Pressure from the Microenvironment
Anderson, A. R. A., Weaver, A. M., Cummings, P. T., & Quaranta, V. (2006) · Cell · doi:10.1016/j.cell.2006.09.042 · Cited by 754
An Introduction to Stochastic Processes.
Kiefer, J., & Bartlett, M. S. (1956) · The American Mathematical Monthly · doi:10.2307/2306456 · Cited by 749
GOODMAN, L. S. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870380008004 · Cited by 700
Models for the Growth of a Solid Tumor by Diffusion
Greenspan, H. P. (1972) · Studies in Applied Mathematics · doi:10.1002/sapm1972514317 · Cited by 581
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M., Sos, M. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002356 · Cited by 525
Self-citationCell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Shah, M. A., & Schwartz, G. K. (2001) · PubMed · Cited by 518
The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
Goldie, J. H., & Coldman, A. J. (1984) · PubMed · Cited by 511
Growth of nonnecrotic tumors in the presence and absence of inhibitors
Byrne, H. M., & Chaplain, M. A. J. (1995) · Mathematical Biosciences · doi:10.1016/0025-5564(94)00117-3 · Cited by 467
Tumor size, sensitivity to therapy, and design of treatment schedules.
Norton, L., & Simon, R. M. (1977) · PubMed · Cited by 447
HER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
Drug resistance in cancer: Principles of emergence and prevention
Komarova, N. L., & Wodarz, D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501870102 · Cited by 414
Drug interactions and the evolution of antibiotic resistance
Yeh, P. J., Hegreness, M. J., Aiden, A. P., & Kishony, R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2133 · Cited by 350 · cited 2×
“Recent studies have shown that drug antagonism between antibiotics may slow the evolution of bacterial resistance (Yeh et al., 2009).”
BackgroundThe initial clinical trial of nitrogen mustard
Gilman, A. (1963) · The American Journal of Surgery · doi:10.1016/0002-9610(63)90232-0 · Cited by 338
Variability and Robustness in T Cell Activation from Regulated Heterogeneity in Protein Levels
Feinerman, O., Veiga, J., Dorfman, J. R., Germain, R. N., & Altan-Bonnet, G. (2008) · Science · doi:10.1126/science.1158013 · Cited by 338
He, S., Liu, Z., Oh, D.-Y., & Thiele, C. J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00001 · Cited by 325
An Introduction to Stochastic Processes with Special Reference to Methods and Applications.
Buckland, W. R., & Bartlett, M. S. (1961) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2984137 · Cited by 323
Ceramide glycosylation potentiates cellular multidrug resistance
LIU, Y., HAN, T., GIULIANO, A. E., & CABOT, M. C. (2001) · The FASEB Journal · doi:10.1096/fj.00-0223com · Cited by 303
The Distribution of Fitness Effects Among Beneficial Mutations
Orr, H. A. (2003) · Genetics · doi:10.1093/genetics/163.4.1519 · Cited by 273
Panetta, J. C. (1996) · Bulletin of Mathematical Biology · doi:10.1007/bf02460591 · Cited by 233
Evolution of Resistance During Clonal Expansion
Iwasa, Y., Nowak, M. A., & Michor, F. (2006) · Genetics · doi:10.1534/genetics.105.049791 · Cited by 233
Self-citation(1949) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb68027.x · Cited by 215
Quantitative model for multiple levels of drug resistance in clinical tumors.
Goldie, J. H., & Coldman, A. J. (1983) · PubMed · Cited by 191
Therapy of Choriocarcinoma and Related Trophoblastic Tumors with Folic Acid and Purine Antagonists
Li, M. C., Hertz, R., & Bergenstal, D. M. (1958) · New England Journal of Medicine · doi:10.1056/nejm195807102590204 · Cited by 189
Sarkar, S., Ma, W. T., & Sandri, G. V. H. (1992) · Genetica · doi:10.1007/bf00120324 · Cited by 181
Jackson, T. L., & Byrne, H. M. (2000) · Mathematical Biosciences · doi:10.1016/s0025-5564(99)00062-0 · Cited by 175
Viruses as antitumor weapons: defining conditions for tumor remission.
Wodarz, D. (2001) · PubMed · Cited by 174
Role of oncogenes in resistance and killing by cancer therapeutic agents
El-Deiry, W. S. (1997) · Current Opinion in Oncology · doi:10.1097/00001622-199701000-00013 · Cited by 170
Progress of a half century in the study of the Luria-Delbrück distribution
Zheng, Q. (1999) · Mathematical Biosciences · doi:10.1016/s0025-5564(99)00045-0 · Cited by 144 · cited 5×
“Many of these contributions are discussed in reviews by Zheng (1999) and Skipper (1983).”
BackgroundInfluentialGöker, E., Waltham, M. C., Kheradpour, A., Trippett, T. M., Mazumdar, M., Elisseyeff, Y., Schnieders, B., Steinherz, P. G., Tan, C. W., & Berman, E. (1995) · Blood · doi:10.1182/blood.v86.2.677.bloodjournal862677 · Cited by 143
Henning, W., & Stürzbecher, H.-W. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00291-9 · Cited by 143
A stochastic model for the origin and treatment of tumors containing drug-resistant cells
Coldman, A. J., & Goldie, J. H. (1986) · Bulletin of Mathematical Biology · doi:10.1007/bf02459682 · Cited by 143
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
Skaggs, B. J., Gorre, M. E., Ryvkin, A., Burgess, M. R., Xie, Y., Han, Y., Komisopoulou, E., Brown, L. M., Loo, J. A., Landaw, E. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609239103 · Cited by 142
The statistical theory of bacterial populations subject to mutation.
Armitage, P. (1952) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1952.tb00098.x · Cited by 139
Hahnfeldt, P., Folkman, J., & Hlatky, L. (2003) · Journal of Theoretical Biology · doi:10.1006/jtbi.2003.3162 · Cited by 138
A mathematical model of tumor growth. II. effects of geometry and spatial nonuniformity on stability
Adam, J. (1987) · Mathematical Biosciences · doi:10.1016/0025-5564(87)90010-1 · Cited by 133
Foo, J., & Michor, F. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000557 · Cited by 130
Self-citationStewart, F. M., Gordon, D. M., & Levin, B. R. (1990) · Genetics · doi:10.1093/genetics/124.1.175 · Cited by 126
Growth Curve of an Experimental Solid Tumor Following Radiotherapy
Norton, L., & Simon, R. (1977) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/58.6.1735 · Cited by 126
Kaeda, J., O’Shea, D., Szydlo, R., Olavarría, E., Dazzi, F., Marin, D., Saunders, S. E., Khorashad, J. S., Cross, N. C. P., Goldman, J. M., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3320 · Cited by 122
Stochastic modeling of drug resistance in cancer
Komarova, N. L. (2005) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.08.003 · Cited by 120
Current Advances in Mathematical Modeling of Anti-Cancer Drug Penetration into Tumor Tissues
Kim, M., Gillies, R. J., & Rejniak, K. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00278 · Cited by 118
Tumor growth dynamics: insights into evolutionary processes
Rodriguez-Brenes, I. A., Komarova, N. L., & Wodarz, D. (2013) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2013.05.020 · Cited by 116
Evolution of resistance and progression to disease during clonal expansion of cancer
Durrett, R. T., & Moseley, S. (2009) · Theoretical Population Biology · doi:10.1016/j.tpb.2009.10.008 · Cited by 106
Cell motility and drug gradients in the emergence of resistance to chemotherapy
Wu, A. Y., Loutherback, K., Lambert, G., Estévez-Salmerón, L., Tlsty, T. D., Austin, R. H., & Sturm, J. C. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314385110 · Cited by 102
Foo, J., Chmielecki, J., Pao, W. J., & Michor, F. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826146ee · Cited by 93
Self-citationEvolutionary dynamics of escape from biomedical intervention
Iwasa, Y., Michor, F., & Nowak, M. A. (2003) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2003.2539 · Cited by 91
Self-citationMaley, C. C., Reid, B. J., & Forrest, S. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.1375.13.8 · Cited by 89
Evolution of resistance to anti-cancer therapy during general dosing schedules
Foo, J., & Michor, F. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.11.022 · Cited by 86
Self-citationEffect of Cellular Quiescence on the Success of Targeted CML Therapy
Komarova, N. L., & Wodarz, D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000990 · Cited by 86
Mutation and growth rates from Luria-Delbrück fluctuation tests.
Koch, A. L. (1982) · Mutation Research · doi:10.1016/0027-5107(82)90252-4 · Cited by 81
Optimal control for a stochastic model of cancer chemotherapy.
Coldman, A., & Murray, J. M. (2000) · Mathematical Biosciences · doi:10.1016/s0025-5564(00)00045-6 · Cited by 76
The Evolution of Two Mutations During Clonal Expansion
Haeno, H., Iwasa, Y., & Michor, F. (2007) · Genetics · doi:10.1534/genetics.107.078915 · Cited by 75
Self-citationMandelbrot, B. (1974) · Journal of Applied Probability · doi:10.2307/3212688 · Cited by 70
Schulte, A., Liffers, K., Kathagen, A., Riethdorf, S., Zapf, S., Merlo, A., Kolbe, K., Westphal, M., & Lamszus, K. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not093 · Cited by 65
A generalized Luria–Delbrück model
Dewanji, A., Luebeck, E. G., & Moolgavkar, S. H. (2005) · Mathematical Biosciences · doi:10.1016/j.mbs.2005.07.003 · Cited by 64
Mumenthaler, S. M., Foo, J., Leder, K., Choi, N. C., Agus, D. B., Pao, W. J., Mallick, P., & Michor, F. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200270v · Cited by 61
Self-citationLeder, K., Foo, J., Skaggs, B. J., Gorre, M. E., Sawyers, C. L., & Michor, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027682 · Cited by 60
Self-citationOptimization of Human Cancer Radiotherapy
Swan, G. W. (1981) · Lecture notes in biomathematics · doi:10.1007/978-3-642-46441-6 · Cited by 58
Togashi, Y., Masago, K., Fukudo, M., Terada, T., Ikemi, Y., Kim, Y. H., Fujita, S., Irisa, K., Sakamori, Y., Mio, T., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d32287 · Cited by 56
On the Choice of a Mathematical Model to Represent Normal Bacterial Growth
Kendall, D. G. (1952) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/j.2517-6161.1952.tb00100.x · Cited by 56
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias
Soverini, S., Iacobucci, I., Baccarani, M., & Martinelli, G. (2007) · Haematologica · doi:10.3324/haematol.11248 · Cited by 53
An explicit representation of the Luria-Delbrück distribution
Angerer, W. P. (2001) · Journal of Mathematical Biology · doi:10.1007/s002850000053 · Cited by 53
Komarova, N. L., Katouli, A. A., & Wodarz, D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004423 · Cited by 53
Stochastic Analysis of Intermediate Lesions in Carcinogenesis Experiments
Luebeck, E. G., & Moolgavkar, S. H. (1991) · Risk Analysis · doi:10.1111/j.1539-6924.1991.tb00585.x · Cited by 52
Modelling chemotherapy resistance in palliation and failed cure
Monro, H. C., & Gaffney, E. A. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.12.006 · Cited by 50
Mathematical models for estimating mutation rates in cell populations
CRUMP, K. S., & HOEL, D. G. (1974) · Biometrika · doi:10.1093/biomet/61.2.237 · Cited by 44
Komarova, N. L., & Wodarz, D. (2007) · Theoretical Population Biology · doi:10.1016/j.tpb.2007.08.003 · Cited by 38
Quantitative models of nuclear transport
Becskei, A., & Mattaj, I. W. (2004) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2004.12.010 · Cited by 34
The Worst Drug Rule Revisited: Mathematical Modeling of Cyclic Cancer Treatments
Katouli, A. A., & Komarova, N. L. (2010) · Bulletin of Mathematical Biology · doi:10.1007/s11538-010-9539-y · Cited by 32
The fixed-size Luria–Delbruck model with a nonzero death rate
Komarova, N. L., Wu, L., & Baldi, P. (2007) · Mathematical Biosciences · doi:10.1016/j.mbs.2007.04.007 · Cited by 31
Ponatinib for Chronic Myeloid Leukemia
Goldman, J. M. (2012) · New England Journal of Medicine · doi:10.1056/nejme1210796 · Cited by 26
Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies
Burgess, M. R., & Sawyers, C. L. (2006) · The Scientific World JOURNAL · doi:10.1100/tsw.2006.184 · Cited by 24
On the role of endothelial progenitor cells in tumor neovascularization
Komarova, N. L., & Mironov, V. (2005) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.01.014 · Cited by 23
Foo, J., Leder, K., & Mumenthaler, S. M. (2012) · Evolutionary Applications · doi:10.1111/eva.12019 · Cited by 21
Self-citationd’Onofrio, A., Gandolfi, A., & Gattoni, S. (2012) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2012.07.025 · Cited by 21
On Bartlett’s formulation of the Luria–Delbrück mutation model
Zheng, Q. (2008) · Mathematical Biosciences · doi:10.1016/j.mbs.2008.05.005 · Cited by 16
Accumulation of neutral mutations in growing cell colonies with competition
Sorace, R., & Komarova, N. L. (2012) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2012.08.015 · Cited by 9
Asymptotics of the Luria-Delbrück distribution
Goldie, C. (1995) · Journal of Applied Probability · doi:10.2307/3215135 · Cited by 8
Cited by
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009
The mathematics of cancer: integrating quantitative models
Altrock, P. M., Liu, L. L., & Michor, F. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4029 · Cited by 685
Self-citationCRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., Schubert, M. S., Friedmann-Morvinski, D., Cohen, Z. R., Behlke, M. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc9450 · Cited by 614
A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity
Waclaw, B., Bozic, I., Pittman, M. E., Hruban, R. H., Vogelstein, B., & Nowak, M. A. (2015) · Nature · doi:10.1038/nature14971 · Cited by 486
The evolution of tumour phylogenetics: principles and practice
Schwartz, R., & Schäffer, A. A. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.170 · Cited by 318
Metadata
- Authors
- Foo, J., & Michor, F.
- Venue
- Journal of Theoretical Biology
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 355
- Pages
- 10-20
- ISSN
- 0022-5193 (ISSN-L)
- OpenAlex
- W2155582899
- Cited by
- 254
- References
- 98
- FWCI
- 21.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.